RxDoctor Payments DataLook up a doctor →

Herbert Bonkovsky, MD

Gastroenterology · Winston Salem, NCNPI 1821093592

Payments from drug & device makers

$1,714,747in general payments, 2019–2025

Across 233 payments — averaging $7359.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mitsubishi Tanabe Pharma Development America, Inc.$731K
  • Gilead$419K
  • Tanabe Pharma America, Inc.$271K
  • Alnylam Pharmaceuticals Inc.$269K
  • Recordati_rare_diseases_inc.$8K
  • HRA Pharma$7K
  • plus $9K from 13 others
$2,010in research payments, 2019–2025

Across 14 payments — averaging $143.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gilead$2K

What the payments were for

  • Consulting fees$21,38538%
  • Speaking & faculty fees$11,68621%
  • Travel & lodging$20,37736%
  • Food & beverage$3,1396%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,714,747 in reported general payments places this provider in the 95th percentile of 610 gastroenterology providers in North Carolina.

See all gastroenterology providers in North Carolina

Medicare billing

Part B allowed, 2024
$8,016
Medicare patients
66
Services billed
80

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin31$118,304
VemlidyTenofovir Alafenamide12$16,261
EliquisApixaban17$11,153
Ursodiol50$5,853
Lactulose20$908
Mycophenolate Mofetil15$573
Spironolactone31$495
Carvedilol52$128
Furosemide36$123
Pantoprazole Sodium14$31

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadVemlidy$419,450$16,26112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 610 gastroenterology providers in North Carolina.

Other gastroenterology in Winston Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →